All News

Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move.

While pharma is not synchronized with the boom and bust of the general economy, lessons from the business cycle facing manufacturers can enable the pharmaceutical industry to tackle the problems it faces, writes Chris Hart of McKinney Rogers.

15 September 2009

Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011.

With the pending retirement of three senior-level executives, Roche announced a new corporate executive team to bridge the personnel gap while the company looks for new leaders.

Some shareholders think they were shafted in the multi-billion dollar deal between Sepracor and Dainippon Sumitomo Pharma. They're so miffed, in fact, that they've filed a lawsuit stating that the amount offered undervalues the company and its shares.

Times are changing in the pharmaceutical and life sciences sectors and their supply chains are having to adapt to a new set of challenges, says Kenneth Porter of specialist consultancy Total Logistics.

Ravi Shankar asks how pharmaceutical firms can best organise the vast amounts of data needed to stay in compliance with issues such as physician spend management.

Physician Spend Management: How Health and Life Sciences Companies Can Simplify Compliance with Master Data Management - Siperian Whitepaper

2 September 2009

Pharma steps up development of new vaccines and treatments to combat Third World diseases

Mastery of internal factors can mean the difference between thriving and failing in an environment where industry is a price taker, not a price setter.

The Executive Guide to Contracts & Chargebacks Management - CDC PE Whitepaper

06 August 2009

21 August 2009

Inside Outsourcing 2009

18 August 2009

04 August 2009

3 August 2009

Dietary supplements function like drugs and are marketed like drugs. They should be regulated like ducks.

Through innovative patient compliance programs, manufacturers are taking steps to meet the needs of patients and the pharma industry.

Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved.

30 July 2009

The drug giant, last week, started tweeting about corporate initiatives, job openings, and news. Is Pfizer just jumping on the bandwagon, or is Twitter part of the company's social media strategy? Pharm Exec talks to Pfizer to find out more.

Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra.

With thousands of UPLC systems and UPLC columns delivered worldwide, see why the world's top-branded companies and institutions have standardized on ACQUITY UPLC: the fastest-growing new LC platform in the market for five years running.

Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine.